2018 Diabetes Drug Development 
Express Pharma
APRIL 17, 2024
Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5 GlobalData’s Pharma Intelligence Center Deals Database reveals that MASH drugs secured over $5.7
pharmaphorum
JANUARY 6, 2021
million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. The nomination of a first candidate in the collaboration that will advance into development triggers a $2.5
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 30, 2022
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. In addition to these issues, further barriers to drug access remain in the UK and US.
European Pharmaceutical Review
SEPTEMBER 21, 2023
In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments. 4,5 What is the key consideration drug developers should apply to gene therapies?
Pharmaceutical Technology
NOVEMBER 30, 2022
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. In addition to these issues, further barriers to drug access remain in the UK and US.
Pharmaceutical Technology
MAY 19, 2023
It received approval from the US Food and Drug Administration in October 2018. Yutiq is indicated to treat chronic, non-infectious uveitis that affects the posterior segment of the eye.
pharmaphorum
JUNE 8, 2022
of working adults in the US report sleeping six or fewer hours per night in 2018, an increase of 4.2% However, the health conditions that can arise from long-term insufficient sleep are far more serious: mental health disorders, immunodeficiency, diabetes, cardiovascular disease, obesity, hormone imbalances, and chronic pain or inflammation.
Expert insights. Personalized for you.
95 
Let's personalize your content